OncoMatch/Neuroendocrine Tumor (NET)/SSTR (somatostatin receptor)
Neuroendocrine Tumor (NET)SSTR (somatostatin receptor) Clinical Trials
Somatostatin receptor (SSTR) positivity — assessed by 68Ga-DOTATATE/DOTATOC PET or In-111 octreoscan — defines eligibility for peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (Lutathera), which is FDA-approved for SSTR-positive gastroenteropancreatic NETs. SSTR expression also guides somatostatin analogue (octreotide, lanreotide) use. Trials investigate 177Lu-DOTATATE in SSTR-positive lung and other NETs, actinium-225 DOTATATE, and combinations with targeted agents.
Top recruiting SSTR (somatostatin receptor) Neuroendocrine Tumor (NET) trials
Ranked by phase and US site count.
See all trials matched to your profile →Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Crinetics Pharmaceuticals Inc.
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
University of Iowa
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Weill Medical College of Cornell University
FDA-approved therapies for SSTR (somatostatin receptor) Neuroendocrine Tumor (NET)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.
Browse other molecular targets with active Neuroendocrine Tumor (NET) trials.